This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Four treatment strategies were examined: no treatment; treatment with cotrimoxazole prophylaxis alone when the CD4 count was <200 cells/μL; treatment with ART alone when the CD4 count was <350 cells/μL; and treatment with ART (CD4 count <350 cells/μL) plus cotrimoxazole (CD4 count <200 cells/μL).
Location/setting
Caribbean/secondary care.
Methods

Analytical approach:
A state-transition model of HIV disease (an adaptation of the cost-effectiveness of preventing AIDS complications US model) was used to facilitate the synthesis of the cost and clinical data. A lifetime horizon was used. The authors stated that the study perspective was that of society.
Effectiveness data:
The effectiveness data were taken from a wide range of sources including the Jamaican Ministry of Health HIV/AIDS Tracking System and the US Multicenter AIDS Cohort Study, as well as published literature. The authors did not report any search methods or inclusion criteria for the studies providing effectiveness data. The main clinical parameters were drug efficacy, the monthly probability of complications from opportunistic disease, and death.
Monetary benefit and utility valuations:
None. The measure of benefit was the number of life-years saved.
Measure of benefit:
Cost data:
The cost categories included medications, inpatient and outpatient care and tests. The costs for ART and cotrimoxazole were taken from the regional Organisation of the Eastern Caribbean States (OECS) pharmaceutical procurement service, while the costs of inpatient and outpatient care were calculated from data taken from the World Health Organization's study on choosing interventions that are cost-effective. The use of inpatient and outpatient HIV medical care related to the USA and was taken from the HIV Research Network study. The costs were converted into 2006 US dollars ($) using a country-specific gross domestic product deflator and the fixed exchange rate between the Eastern Caribbean dollar and the US dollar. A discount rate of 3% was applied to the costs.
Analysis of uncertainty:
A sensitivity analysis was performed on some of the clinical and cost data. The authors did not report the type of sensitivity analysis conducted, but it appears to have been a one-way analysis. The results of the sensitivity analysis were shown as upper and lower limits around the incremental cost-effectiveness ratio.
Results
The mean life expectancy with no treatment was 2.3 years at a lifetime cost of $1,600 per person.
Treatment using one line of ART resulted in a mean life expectancy of 8.04 years at a cost of $5,520, giving an incremental cost-effectiveness ratio (ICER) of $690 per year of life saved compared with the option of no treatment.
Treatment using one line of ART with cotrimoxazole produced a mean life expectancy of 8.16 years at a cost of $5,620, giving an ICER of $830 per year of life saved.
Finally, treatment with two lines of ART with cotrimoxazole increased mean life expectancy to 9.20 years at a cost of $17,020 per person, giving an ICER of $10,960 per life year saved.
The cost of second-line ART and the strategies used to switch between therapies had the greatest impact on costeffectiveness. For example, the ICER of treatment with two lines of ART decreased from $10,960 to $3,530 if the monthly cost of second-line ART decreased to the international cost.
